Get the Stockscreener App
33.34
0.54%
0.18
After Hours:
33.34
Cg Oncology Inc stock is traded at $33.34, with a volume of 1.40M.
It is up +0.54% in the last 24 hours and up +33.63% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$33.16
Open:
$32.98
24h Volume:
1.40M
Relative Volume:
1.62
Market Cap:
$2.54B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-26.25
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+0.82%
1M Performance:
+33.63%
6M Performance:
+25.24%
1Y Performance:
-4.28%
1-Day Range:
$32.57
$34.46
1-Week Range:
$32.08
$34.73
52-Week Range:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
33.34 | 2.56B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology, Inc. $CGON Shares Sold by Corebridge Financial Inc. - MarketBeat
Analysts Set CG Oncology, Inc. (NASDAQ:CGON) PT at $54.30 - MarketBeat
Analysts Offer Insights on NA Companies: Reddit Inc Class A (RDDT), Solventum Corporation (SOLV) and CG Oncology, Inc. (CGON) - The Globe and Mail
James Mulay Sells 27,015 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial - Yahoo Finance
Northern Trust Corp Grows Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Jones Trading Begins Coverage on CG Oncology (NASDAQ:CGON) - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology Highlights Drug Potential at Healthcare Conference - MSN
Can technical indicators confirm CG Oncology Inc.’s reversalMarket Volume Report & Free High Accuracy Swing Entry Alerts - Newser
Earnings visualization tools for CG Oncology Inc.CPI Data & Safe Capital Growth Tips - Newser
Is CG Oncology Inc. showing signs of accumulationPortfolio Value Summary & Weekly Consistent Profit Watchlists - Newser
Alliancebernstein L.P. Has $46.10 Million Position in CG Oncology, Inc. $CGON - MarketBeat
Combining price and volume data for CG Oncology Inc.2025 Market Overview & Fast Moving Stock Watchlists - Newser
What momentum shifts mean for CG Oncology Inc.Market Activity Report & Growth Oriented Trade Recommendations - Newser
Using flow based indicators on CG Oncology Inc.July 2025 Market Mood & Safe Entry Trade Reports - Newser
CG Oncology (NASDAQ:CGON) Now Covered by Jones Trading - Defense World
Should you hold or exit CG Oncology Inc. nowPrice Action & Low Drawdown Momentum Ideas - Newser
What machine learning models say about CG Oncology Inc.M&A Rumor & Real-Time Sentiment Analysis - Newser
Is CG Oncology Inc. building a consolidation baseJuly 2025 Earnings & Consistent Growth Equity Picks - Newser
Real time pattern detection on CG Oncology Inc. stockPortfolio Profit Report & Fast Gain Swing Alerts - Newser
Technical signs of recovery in CG Oncology Inc.Quarterly Portfolio Report & Daily Profit Focused Screening - Newser
CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study - Yahoo Finance
CG Oncology stock holds Buy rating at H.C. Wainwright on strong cancer data - Investing.com Canada
Is CG Oncology Inc. stock ready for a breakoutGap Down & Weekly High Return Forecasts - Newser
CG Oncology initiated with a Buy at JonesResearch - TipRanks
JonesTrading Initiates CG Oncology at Buy With $50 Price Target - MarketScreener
Real time alert setup for CG Oncology Inc. performanceBond Market & Entry Point Confirmation Signals - Newser
Real time breakdown of CG Oncology Inc. stock performanceWeekly Stock Recap & Weekly Breakout Watchlists - Newser
What earnings revisions data tells us about CG Oncology Inc.Weekly Trend Report & Smart Money Movement Alerts - Newser
CG Oncology (NASDAQ:CGON) Raised to "Hold" at Zacks Research - MarketBeat
What is the dividend yield of CG Oncology Inc.Quarterly Trade Report & Daily Oversold Bounce Ideas - beatles.ru
Is CG Oncology Inc. stock reversal real or fake2025 Macro Impact & Daily Stock Momentum Reports - Newser
Understanding CG Oncology Inc.’s price movement2025 Price Momentum & Breakout Confirmation Alerts - Newser
ADAR1 Capital Management LLC Has $7.38 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
is cg oncology inc. still worth holding after the dip2025 Market Trends & High Accuracy Swing Entry Alerts - Newser
Using economic indicators to assess CG Oncology Inc. potentialEarnings Overview Report & Safe Entry Momentum Stock Tips - Newser
Using R and stats models for CG Oncology Inc. forecastingTrade Ideas & Weekly High Momentum Picks - Newser
What moving averages say about CG Oncology Inc.Portfolio Profit Report & Expert Verified Movement Alerts - Newser
CG Oncology Inc. stock trend forecastMarket Risk Analysis & Accurate Entry and Exit Point Alerts - Newser
What are CG Oncology Inc.’s technical support levels2025 Short Interest & Community Verified Swing Trade Signals - خودرو بانک
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
CG Oncology reports 41.8% complete response rate at 24 months for bladder cancer drug - Investing.com Canada
Will CG Oncology Inc. outperform the marketTrade Analysis Report & Consistent Profit Focused Trading Strategies - Newser
CG Oncology reports 41.8% complete response rate at 24 months for bladder cancer drug By Investing.com - Investing.com South Africa
CG Oncology stock rises on strong bladder cancer treatment durability data - Investing.com
Is CG Oncology Inc. a candidate for recovery playTrade Volume Report & Real-Time Volume Surge Alerts - Newser
Updated BOND-003 data support durability of cretostimogene grenadenorepvec in NMIBC - Urology Times
CG Oncology stock rises on strong bladder cancer treatment durability data By Investing.com - Investing.com South Africa
Cg Oncology shares rise 5.20% premarket after announcing positive 24-month complete response rate for cretostimogene. - AInvest
CG Oncology Says Investigational Bladder Cancer Drug Shows 'Robust' Response - MarketScreener
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):